IDH2 and neoplasm: In the case of glioblastoma, it is recommended to conduct tests on tumor samples to determine the presence of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and IDH type 1 or type 2 mutations, particularly in patients younger than 55 years